BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Core Insights - BriaCell Therapeutics Corp. has been accepted into Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator 2025 Cohort program to expedite the clinical development of its personalized immunotherapy, Bria-OTS+, for various cancer types [1][2][3] Group 1: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4] - The company is working on Bria-OTS+, a next-generation personalized off-the-shelf immunotherapy targeting multiple cancer indications, including metastatic breast cancer and prostate cancer [1][4] Group 2: Collaboration with MSK - The collaboration with MSK will provide BriaCell access to expertise and resources, including GMP manufacturing services and regulatory strategy support, to accelerate the development of Bria-OTS+ [2][3] - Dr. William V. Williams, BriaCell's President and CEO, expressed that MSK's resources and expertise make it an ideal partner for advancing their immunotherapy platform [3] Group 3: Potential Impact - Dr. Miguel Lopez-Lago, BriaCell's Chief Scientific Officer, stated that Bria-OTS+ has the potential to significantly improve efficacy and safety for thousands of cancer patients [4]